Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 101–200 of 999
Blumberger, D. M., Tran, L. C., Fitzgerald, P. B., Hoy, K. E., & Daskalakis, Z. J. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00074 · Cited by 159
Reilly, T. J., MacGillivray, S. A., Reid, I. C., & Cameron, I. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.008 · Cited by 155
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“…of switching antidepressant classes over continuation of the ongoing antidepressant treatment is supported by findings in other comparable samples of MDD patients (Ruhe et al. 2006; Rush et al. 2006; Bschor and Baethge 2010; Romera et al. 2012; Schosser et al. 2012b; Bschor et al. 2018).”
ResultTrivedi, M. H., Rush, A. J., Gaynes, B. N., Stewart, J. W., Wisniewski, S. R., Warden, D., Ritz, L., Luther, J. F., Stegman, D., DeVeaugh-Geiss, J., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301390 · Cited by 163
“Application of the MBC approach led to similarly aggressive dosing and duration for those not remitting and moving on to level-2 treatment, whether the intervention was pharmacologic augmentation of citalopram (Trivedi et al, 2006a) or switching to a different antidepressant (Rush et al, 2006).”
BackgroundMethodSelf-citationTreatment-resistant depression.
Little, A. A. (2009) · PubMed · Cited by 199
Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness
Albert, P. R., Le François, B., & Millar, A. M. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-21 · Cited by 150
“With current antidepressant treatments, although up to 60% of patients respond, only 30% go on to remission [8-13], and 15% attempt suicide [14,15].”
BackgroundAgomelatine in the Treatment of Major Depressive Disorder: Potential for Clinical Effectiveness
Kennedy, S. H., & Rizvi, S. J. (2010) · CNS Drugs · doi:10.2165/11534420-000000000-00000 · Cited by 160
Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression: A Pilot Study
Eisendrath, S. J., Delucchi, K., Bitner, R., Fenimore, P., Smit, M., & McLane, M. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000142525 · Cited by 148
Pharmacological Treatments for Patients with Treatment-Resistant Depression
Ruberto, V. L., Jha, M. K., & Murrough, J. W. (2020) · Pharmaceuticals · doi:10.3390/ph13060116 · Cited by 147
“There was no significant difference in tolerability between switching to bupropion, sertraline, or venlafaxine [11].”
BackgroundHowland, R., Rush, A., Wisniewski, S., Trivedi, M., Warden, D., Fava, M., Davis, L., Balasubramani, G., McGrath, P., & Berman, S. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.08.010 · Cited by 141
“At baseline, the CRCs completed the HRSD and the 16-item Quick Inventory of Depressive Symptomatology – Clinician-rated (QIDS-C) scale, and collected the self-report version of the QIDS (QIDS-SR) scale (Rush et al., 2000, 2003, 2006a; Trivedi et al., 2004) to assess depressive symptom severity.”
Self-citationMcNeely, H. E., Mayberg, H. S., Lozano, A. M., & Kennedy, S. H. (2008) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0b013e3181710927 · Cited by 146
“…such as medications and psychotherapy (Fava, 2003) and a recent report indicates that more than 50% of patients in “real world” practice failed to achieve remission after measurement-based care with a selective serotonin reuptake inhibitor followed by a second antidepressant (Rush et al., 2006).”
BackgroundTreating Depression and Depression-Like Behavior with Physical Activity: An Immune Perspective
Eyre, H. A., Papps, E., & Baune, B. T. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00003 · Cited by 146
Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants
Lee, S., Lee, S.-J., Han, C., Patkar, A. A., Masand, P. S., & Pae, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.09.008 · Cited by 163
“The famous Sequenced Treatment Alternatives to Relieve Depression (STAR-D) trial achieved initial remission rates of only 28–33%, and these rates declined even further after initial treatment failure (Rush et al., 2006).”
BackgroundParikh, S. V., Zaretsky, A., Beaulieu, S., Yatham, L. N., Young, L. T., Patelis-Siotis, I., MacQueen, G. M., Levitt, A., Arenovich, T., Cervantes, P., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07343 · Cited by 145
Luedtke, A., Sadikova, E., & Kessler, R. C. (2019) · Clinical Psychological Science · doi:10.1177/2167702618815466 · Cited by 143
Mendlewicz, J. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802503086 · Cited by 143
“No more than one-third of the depressed patients who begin treatment achieve full remission, defined as a virtually complete relief of symptoms, and return to full functioning in all areas of life (Thase 2003; McIntyre and O’Donovan 2004; Rush et al. 2006; Trivedi et al. 2006).”
BackgroundPapakostas, G. I. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.03 · Cited by 143
Dunner, D. L., Aaronson, S. T., Sackeim, H. A., Janicak, P. G., Carpenter, L. L., Boyadjis, T., Brock, D. G., Bonneh-Barkay, D., Cook, I. A., Lanocha, K., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08977 · Cited by 142
Bupropion: A Review of its Use in the Management of Major Depressive Disorder
Dhillon, S., Yang, L. P. H., & Curran, M. P. (2008) · Drugs · doi:10.2165/00003495-200868050-00011 · Cited by 156
Multifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy
McClintock, S. M., Choi, J., Deng, Z.-D., Appelbaum, L. G., Krystal, A. D., & Lisanby, S. H. (2014) · The Journal of ECT · doi:10.1097/yct.0000000000000137 · Cited by 141
“For example, the Sequenced Treatment Alternatives to Relieve Depression study found that antidepressant treatment with citalopram resulted in remission rates between 28% and 33%.(1) The Systematic Treatment Enhancement Program for Bipolar Disorder found treatment with an antidepressant (paroxetine or bupropion) and a…”
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
Biomarkers to Predict Antidepressant Response
Leuchter, A. F., Cook, I. A., Hamilton, S. P., Narr, K. L., Toga, A., Hunter, A. M., Faull, K., Whitelegge, J., Andrews, A. M., Loo, J., et al. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0160-4 · Cited by 140
“The current widespread use of SSRIs in treatment of depression has resulted in a large body of literature on SSRI pharmacogenetics [65].”
BackgroundInfluentialBauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., & Sajatovic, M. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.7.927 · Cited by 138
“Underscoring the problems associated with undertreatment, the low medication response rates in recent real-world clinical trials for depression (18,19), schizophrenia (20), and bipolar disorder (21) indicate that more comprehensive approaches for such illnesses are warranted.”
BackgroundEarly intervention for depression in young people: a blind spot in mental health care
Davey, C. G., & McGorry, P. D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30292-x · Cited by 137
Kitaichi, Y., Inoue, T., Nakagawa, S., Boku, S., Kakuta, A., Izumi, T., & Koyama, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.08.026 · Cited by 145
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
Meltzer-Brody, S., & Kanes, S. J. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100212 · Cited by 133
Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why?
Adli, M., Bauer, M., & Rush, A. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.010 · Cited by 159
Self-citationMillan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Bares, M., Brunovsky, M., Kopecek, M., Novak, T., Stopkova, P., Kozeny, J., Sos, P., Krajca, V., & Höschl, C. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.001 · Cited by 132
“Venlafaxine was selected for our study because it is generally well tolerated and evidence about its efficacy in the treatment of resistant depression is relatively strong [3,16,37,43].”
MethodGartlehner, G., Gaynes, B. N., Amick, H. R., Asher, G. N., Morgan, L. C., Coker-Schwimmer, E., Forneris, C., Boland, E., Lux, L. J., Gaylord, S., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1813 · Cited by 132
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“25, 83233 Bernau am Chiemsee, Germany; and Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany; E-mail: a.menke@medicalpark.de [9].”
BackgroundNierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., Tollefson, G. D., & Wohlreich, M. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167453 · Cited by 131
Self-citationCare Management of Poststroke Depression: A Randomized, Controlled Trial
Williams, L. S., Kroenke, K., Bakas, T., Plue, L. D., Brizendine, E., Tu, W., & Hendrie, H. (2007) · Stroke · doi:10.1161/01.str.0000257319.14023.61 · Cited by 130
Avery, D. H., Isenberg, K. E., Sampson, S. M., Janicak, P. G., Lisanby, S. H., Maixner, D. F., Loo, C., Thase, M. E., Demitrack, M. A., & George, M. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0315 · Cited by 129
“Specifically, in STAR*D, remission rates after 1 and 2 unsuccessful courses of antidepressant therapy were 21% and 16%, respectively.(16) In the current study of TMS, the HAM-D-17 remission rates after 1 and 2 unsuccessful courses were 25.”
BackgroundSelf-citationWiles, N., Thomas, L., Abel, A., Barnes, M., Carroll, F., Ridgway, N., Sherlock, S., Turner, N., Button, K., Odondi, L., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18310 · Cited by 127
Communicating Medical News — Pitfalls of Health Care Journalism
Dentzer, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0805753 · Cited by 127
Etkin, A., Patenaude, B., Song, Y. J. C., Usherwood, T., Rekshan, W. R., Schatzberg, A. F., Rush, A. J., & Williams, L. M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.333 · Cited by 143
Self-citationDiduch, M., Milovac, R., & Thomas, C. (2017) · PharmacotherapyFirst: A Multimedia Learning Resource · doi:10.21019/pharmacotherapyfirst.mdd_overview · Cited by 122
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
“is lower among patients who failed two treatments [4].”
BackgroundA critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression
Eyre, H. A., Air, T., Proctor, S. J., Rositano, S., & Baune, B. T. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.10.003 · Cited by 132
“Additionally, more than 50% of patients on antidepressants will not achieve remission following initial treatment (Trivedi et al., 2006), and nearly one-third will not achieve remission even following several treatment steps (Rush et al., 2006a,b).”
BackgroundInfluentialLeuchter, A., Cook, I., Gilmer, W., Marangell, L., Burgoyne, K., Howland, R., Trivedi, M., Zisook, S., Jain, R., Fava, M., et al. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2009.04.004 · Cited by 117
Self-citationRubino, A., Roskell, N., Tennis, P., Mines, D., Weich, S., & Andrews, E. (2007) · BMJ · doi:10.1136/bmj.39041.445104.be · Cited by 121
Brunelin, J., Jalenques, I., Trojak, B., Attal, J., Szekely, D., Gay, A., Januel, D., Haffen, E., Schott-Pethelaz, A.-M., Brault, C., et al. (2014) · Brain Stimulation · doi:10.1016/j.brs.2014.07.040 · Cited by 119
“This design was used predominantly for ethical reasons as well as for the following reasons: previous studies have reported the superiority of LF rTMS compared to placebo [9,13] and the non-inferiority of LF rTMS compared with venlafaxine [20]; and each of the approaches (rTMS and venlafaxine) has been reported to be…”
BackgroundMethodInfluentialEvidence-based pharmacotherapy of treatment-resistant unipolar depression
Dold, M., & Kasper, S. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1248852 · Cited by 118
“In this trial, citalopram non-responders achieved remission rates between 17.6% and 24.8% after switching to bupropion, sertraline or venlafaxine without identifying any significant differences between the different antidepressant substances (Rush et al. 2006).”
BackgroundInfluentialBlumberger, D. M., Mulsant, B. H., Fitzgerald, P. B., Rajji, T. K., Ravindran, A. V., Young, L. T., Levinson, A. J., & Daskalakis, Z. J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.579163 · Cited by 118
“…of the treatments investigated in the third and fourth level of the Sequenced Treatment Alternatives to Relieve Depression (STAR ∗ D) study and comparable to the rates of remission at level two (Fava et al. 2006; McGrath et al. 2006; Nierenberg et al. 2006; Rush et al. 2006; Trivedi et al. 2006).”
ResultSouery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., Demyttenaere, K., Kasper, S., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182228619 · Cited by 119
Electroconvulsive Therapy: Evidence and Challenges
Fink, M., & Taylor, M. A. (2007) · JAMA · doi:10.1001/jama.298.3.330 · Cited by 136
Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 2: Study Outcomes
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20081001-05 · Cited by 115
Biochemical markers subtyping major depressive disorder
Kunugi, H., Hori, H., & Ogawa, S. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12299 · Cited by 114
“SSRI and SNRI).(23) In these patients, symptoms such as avolition, psychomotor retardation, poor concentration and anhedonia are likely to persist even after depressed mood and anxiety have resolved.”
BackgroundMöller, H.-J. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970801981606 · Cited by 114
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Giacobbe, P., Mayberg, H. S., & Lozano, A. M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.04.028 · Cited by 112
Trivedi, M. H., & Daly, E. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.01.007 · Cited by 115
“2.3 Residual Symptoms and Functional Impairment in Major Depression The goal of depression treatment is now full remission of symptoms (i.e., absence of symptoms), rather than response (Bakish 2001; Rush et al., 2006b).”
BackgroundMethodInfluentialSelf-citationKunugi, H. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13551 · Cited by 139
“respond to or achieve remission with the current first-line antidepressant therapy.(3) In addition, patients with MDD often show poor adher-”
BackgroundExplaining Patients' Beliefs About the Necessity and Harmfulness of Antidepressants
Aikens, J. E., Nease, D. E., & Klinkman, M. S. (2008) · The Annals of Family Medicine · doi:10.1370/afm.759 · Cited by 109
“Duration of current episode, months, median (IQR) 16 (8-34)”
BackgroundRecognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
“The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study used abrupt switching from citalopram (after a mean duration of treatment of 8 weeks) to one of three alternatives: sertraline, venlafaxine and bupropion (Rush et al , 2006).”
Acupuncture for Depression: A Review of Clinical Applications
Wu, J., Yeung, A. S., Schnyer, R., Wang, Y., & Mischoulon, D. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700702 · Cited by 109
Bauer, M., Tharmanathan, P., Volz, H., Moeller, H., & Freemantle, N. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0849-0 · Cited by 137
“Rush [ 38 ] Bupropion sertraline Adult, non-psychotic major depressive disorder NA 727 1,095 (3 years) NA NK Open-label”
Perlis, R. H., Moorjani, P., Fagerness, J. A., Purcell, S., Trivedi, M. H., Fava, M., Rush, A. J., & Smoller, J. W. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.6 · Cited by 112
Self-citationDepressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?
Moulton, C. D., Pavlidis, P., Norton, C., Norton, S., Pariante, C., Hayee, B., & Powell, N. (2019) · Clinical and Experimental Immunology · doi:10.1111/cei.13276 · Cited by 101
Adli, M., Hollinde, D. L., Stamm, T. J., Wiethoff, K., Tsahuridu, M., Kirchheiner, J., Heinz, A., & Bauer, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.023 · Cited by 111
Berlim, M. T., Fleck, M. P., & Turecki, G. (2008) · Annals of Medicine · doi:10.1080/07853890701769728 · Cited by 100
“This result thus questions the usual clinical practice of changing the group of antidepressant when there is a previous failure with an agent from the same family (65).”
ResultElectroconvulsive therapy increases temporal gray matter volume and cortical thickness
Sartorius, A., Demirakça, T., Böhringer, A., von Hohenberg, C. C., Aksay, S. S., Bumb, J. M., Kranaster, L., & Ende, G. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.036 · Cited by 108
Prins, J., Olivier, B., & Korte, S. M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594039 · Cited by 97
“The rationale for developing a TRI came from indications that augmentation of antidepressant therapy with either the noradrenaline dopamine reuptake inhibitor (NDRI), bupropion [173,174], or the DA receptor agonists [116,117] was clinically effective.”
BackgroundA Systematic Approach to Pharmacotherapy for Geriatric Major Depression
Mulsant, B. H., Blumberger, D. M., Ismail, Z., Rabheru, K., & Rapoport, M. J. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.05.002 · Cited by 99
“citalopram to bupropion, sertraline, or venlafaxine did not differ significantly with respect to outcomes, tolerability, or adverse events.(56,59) Although there is no geriatric study similar to STAR*D, as discussed earlier the efficacy of venlafaxine in older patients who failed to respond to an SSRI is supported by…”
Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
Kudlow, P., McIntyre, R., & Lam, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0171-5 · Cited by 84
“3 Controlled Studies of Early-Switch Strategies While the benefits of switching antidepressant medications after a failed trial have been investigated in many openlabel studies and RCTs [20–22], only three studies have investigated the timing of switch strategies for antidepressant non-responders (Table 2).”
Mouillet‐Richard, S., Baudry, A., Launay, J., & Kellermann, O. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.035 · Cited by 99
Leuchter, A. F., Husain, M. M., Cook, I. A., Trivedi, M. H., Wisniewski, S. R., Gilmer, W. S., Luther, J. F., Fava, M., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006035 · Cited by 98
“Additional adjustments : HAMD17 remission, gender ; QIDS-SR16 percentage change and QIDS-SR16 response, gender and recurrent depression. comparing those with no PPS to those with the most severe complaints (11.1% difference in remission rates).”
MethodInfluentialSelf-citationRybak, Y. E., Lai, K. S. P., Ramasubbu, R., Vila‐Rodriguez, F., Blumberger, D. M., Chan, P., Delva, N., Giacobbe, P., Gosselin, C., Kennedy, S. H., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23135 · Cited by 97
Fleck, M. P., Berlim, M. T., Lafer, B., Sougey, E. B., Porto, J. A. D., Brasil, M. A., Juruena, M. F., & Hetem, L. A. (2009) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462009000500003 · Cited by 97
Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients
Perlis, R. H., Laje, G., Smoller, J. W., Fava, M., Rush, A. J., & McMahon, F. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.4 · Cited by 98
“Following citalopram treatment at doses up to 60 mg per day for up to 14 weeks, participants who did not achieve remission (QIDS-C16p5) and/or who could not tolerate citalopram were encouraged to proceed to next-step treatments.”
InfluentialSelf-citationInserra, A., Mastronardi, C. A., Rogers, G., Licinio, J., & Wong, M.-L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1359-3 · Cited by 96
MahmoudianDehkordi, S., Ahmed, A. T., Bhattacharyya, S., Han, X., Baillie, R. A., Arnold, M., Skime, M. K., John-Williams, L. S., Moseley, M. A., Thompson, J. W., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01097-6 · Cited by 95
Self-citationStepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study
Kroenke, K., Bair, M. J., Damush, T. M., Hoke, S., Nicholas, G., Kempf, C., Huffman, M. A., Wu, J., & Sutherland, J. M. (2007) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.08.005 · Cited by 99
“Prioritization of antidepressant selection For depression per se, there is no evidence that one antidepressant is superior to another in terms of efficacy [89,90].”
BackgroundKayser, S., Bewernick, B. H., Matusch, A., Hurlemann, R., Soehle, M., & Schlaepfer, T. E. (2015) · Psychological Medicine · doi:10.1017/s0033291714002244 · Cited by 94
“In approximately 50% of patients, first-line antidepressant treatment is ineffective and about a third of patients do not show a substantial antidepressant response, even after four treatment steps (Rush et al. 2006; Lisanby et al. 2009).”
BackgroundBareš, M., Brunovský, M., Novák, T., Kopeček, M., Stopková, P., Šóš, P., Krajča, V., & Höschl, C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.03.007 · Cited by 100
Bauer, M., Pfennig, A., Linden, M., Smolka, M. N., Neu, P., & Adli, M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ac4839 · Cited by 94
Pigott, H. E. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000104 · Cited by 93
Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063095 · Cited by 93
Artigas, F., Bortolozzi, A. A., & Celada, P. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.10.032 · Cited by 102
“The STAR*D study also showed that the overall remission rate increased to 67% after four sequenced treatments with different antidepressant drugs during 1 yr (Rush et al., 2006b).”
BackgroundResultMalhi, G. S., Outhred, T., Hamilton, A., Boyce, P. M., Bryant, R., Fitzgerald, P. B., Lyndon, B., Mulder, R., Murray, G., Porter, R. J., et al. (2018) · Medical Journal of Australia · doi:10.5694/mja17.00659 · Cited by 92
Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database
Serna, M. C., Cruz, I., Real, J., Gascó, E., & Galván, L. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2009.07.012 · Cited by 91
“Although it has been suggested that the efficacy of second-generation antidepressants is similar among patients for whom treatment with a firstline agent failed, a substantial proportion of these patients do not achieve response or remission with second-line treatment [24].”
BackgroundPharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., Filippis, R. D., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 91
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
A new paradigm for the prediction of antidepressant treatment response
Leuchter, A. F., Cook, I. A., Hunter, A. M., & Korb, A. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/afleuchter · Cited by 90
“The results from level II treatment in STAR*D suggested that patients respond or remit to different antidepressants at similar rates, regardless of the MOA.(19,20) The sole reliable predictor of improvement in sequential treatment is that improvement at one step is associated with further improvement at the next step,…”
InfluentialRevitalizing Psychiatric Therapeutics
Hyman, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.181 · Cited by 98
“Many patients with depression (most notably bipolar depression) and anxiety disorders have substantial residual symptoms despite optimal use of current treatments (Rush et al, 2006; Sachs et al, 2007).”
BackgroundArabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.056 · Cited by 89
Mariani, N., Cattane, N., Pariante, C. M., & Cattaneo, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01469-6 · Cited by 111
Sheehan, D. V., Keene, M. S., Eaddy, M. T., Krulewicz, S., Kraus, J. E., & Carpenter, D. J. (2008) · CNS Drugs · doi:10.2165/00023210-200822110-00005 · Cited by 110
Rajpurkar, P., Yang, J., Dass, N., Vale, V., Keller, A. S., Irvin, J., Taylor, Z., Basu, S., Ng, A., & Williams, L. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.6653 · Cited by 88
Mechanisms underlying the antidepressant response and treatment resistance
Levinstein, M. R., & Samuels, B. A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00208 · Cited by 99
Jha, M., & Trivedi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010233 · Cited by 86
“Hence, the current clinical practice continues to be a trial-and-error process that necessitates multiple treatment trials to attain adequate symptomatic control for a majority of patients [20,21].”
BackgroundSelf-citationAntidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression
Lenze, E. J., Mulsant, B. H., Roose, S. P., Lavretsky, H., Reynolds, C. F., Blumberger, D. M., Brown, P. J., Cristancho, P., Flint, A. J., Gebara, M. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204462 · Cited by 110
Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects
Gorlyn, M., Keilp, J. G., Grunebaum, M. F., Taylor, B. P., Oquendo, M. A., Bruder, G. E., Stewart, J. W., Zalsman, G., & Mann, J. J. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0084-x · Cited by 84
“Only 40% of patients achieve remission with their initial antidepressant trial (Rush et al. 2006), and the need for successive interventions because of poor clinical response prolongs the period of illness.”
BackgroundSelf-citationWright, B. M., Eiland, E. H., & Lorenz, R. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1204 · Cited by 84
“Evidence from the Sequenced Treatment Alternatives to Relieve Depression trials (STAR*D) showed that one in four patients who did not respond to their first antidepressant responded to a trial with a different agent.(4) Some augmentation strategies that have been studied include the addition of the NDRI bupropion, bus…”
MethodZandvakili, A., Philip, N. S., Jones, S. R., Tyrka, A. R., Greenberg, B. D., & Carpenter, L. L. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.077 · Cited by 82
“Conventional pharmacologic and behavioral treatments fail to provide adequate relief for many individuals with either illness (Rush et al., 2006).”
BackgroundShen, Y., Yao, J., Jiang, X., Zhang, L., Xu, L., Feng, R., Cai, L., Liu, J., Wang, J., & Chen, W. (2015) · Human Brain Mapping · doi:10.1002/hbm.22817 · Cited by 83
“Moreover, patients with MDD who fail to show early improvement in response to an initial antidepressant treatment are demonstrated to benefit from timely switching of treatment strategies and, therefore, improved final outcome [Nakajima et al., 2011; Rush et al., 2006].”
Background
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.